Cargando…

Bull's eye maculopathy and subfoveal deposition in two mucopolysaccharidosis type I patients on long-term enzyme replacement therapy

PURPOSE: To report retinal findings in two patients with mucopolysaccharidosis type I (MPS I) receiving human recombinant alpha-l-iduronidase (Laronidase) as enzyme replacement therapy. OBSERVATIONS: Patient 1 had visual acuity 20/20 right eye, 20/25 left eye and unremarkable anterior segment and re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mack, Heather G., Symons, R.C. Andrew, de Jong, Gerard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Case report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786832/ https://www.ncbi.nlm.nih.gov/pubmed/29468207 http://dx.doi.org/10.1016/j.ajoc.2017.10.006

Ejemplares similares

Ritonavir and bull’s eye maculopathy: case report
por: Pinto, Rita, et al.
Publicado: (2013)

Bull's eye maculopathy associated with hereditary hemochromatosis
por: Bellsmith, Kellyn N., et al.
Publicado: (2020)

Near-infrared reflectance bull’s eye maculopathy as an early indication of hydroxychloroquine toxicity
por: Wong, Keye L, et al.
Publicado: (2015)

Bull’s Eye Maculopathy in Near-Infrared Reflectance as An Early Sign of Hydroxychloroquine Toxicity
por: Santos, Miguel, et al.
Publicado: (2023)

Pseudovitelliform Subfoveal Deposit in Waldenström's Macroglobulinemia
por: Brolly, Aurélie, et al.
Publicado: (2012)

Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I
por: Nestrasil, Igor, et al.
Publicado: (2017)

Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I
por: Ghosh, Arunabha, et al.
Publicado: (2019)

Changes in parafoveal retinal thickness and subfoveal choroidal thickness in a patient with dengue fever-associated maculopathy
por: Yamamoto, Kazuhiro, et al.
Publicado: (2013)

Effects of Enzyme Replacement Therapy Started Late in a Murine Model of Mucopolysaccharidosis Type I
por: Pasqualim, Gabriela, et al.
Publicado: (2015)

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO
por: Tang, Fen, et al.
Publicado: (2019)

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II
por: Schulze-Frenking, G., et al.
Publicado: (2010)

Mucopolysaccharidosis: Cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI
por: Brands, Marion M. M. G., et al.
Publicado: (2012)

Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network
por: Dornelles, Alícia Dorneles, et al.
Publicado: (2014)

A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I
por: Le, Steven Q., et al.
Publicado: (2017)

Removal of Subfoveal Massive Hard Exudates through an Intentional Macular Hole in Patients with Diabetic Maculopathy: A Report of Three Cases
por: Iwane, Yukako, et al.
Publicado: (2022)

Subfoveal Choroidal Thickness and Glaucoma. The Beijing Eye Study 2011
por: Wang, Ya Xing, et al.
Publicado: (2014)

BULL'S EYE MACULOPATHY POSSIBLY DUE TO IRON OVERLOAD IN A CHILD WITH THALASSEMIA MAJOR: A CASE OF POSSIBLE “FERRITIN RETINOPATHY”
por: Abraham, Anina
Publicado: (2021)

Mucopolysaccharidosis Type I Diagnosed by Aortic and Mitral Valve Replacement
por: Sherwood, Dalton J., et al.
Publicado: (2021)

Long-term evolution of mucopolysaccharidosis type I in twins treated with enzyme replacement therapy plus hematopoietic stem cells transplantation
por: Carbajal-Rodríguez, Luis M., et al.
Publicado: (2021)

Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(®)) therapy
por: Braunlin, E., et al.
Publicado: (2012)

Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease
por: Hsu, Yu-Hone, et al.
Publicado: (2017)

Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice
por: Kida, Sachiho, et al.
Publicado: (2023)

Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA
por: Lin, Hsiang-Yu, et al.
Publicado: (2018)

Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II
por: Seo, Joo-Hyun, et al.
Publicado: (2021)

Diurnal variation in subfoveal and peripapillary choroidal vascularity index in healthy eyes
por: Singh, Sumit Randhir, et al.
Publicado: (2019)

Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series
por: Lin, Hsiang-Yu, et al.
Publicado: (2016)

Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome)
por: Sohn, Young Bae, et al.
Publicado: (2013)

Cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type I
por: Sugiura, Kenta, et al.
Publicado: (2020)

Treatment of latent tuberculosis in a child with mucopolysaccharidosis type I receiving enzyme replacement therapy: A case report
por: Vasilevska, Lauma, et al.
Publicado: (2022)

Effects of refractive accommodation on subfoveal choroidal thickness in silicone oil-filled eyes
por: Yan, Ying, et al.
Publicado: (2022)

12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment
por: Gabrielli, Orazio, et al.
Publicado: (2016)

Real-world data assessment of safety of home-based and hospital/outpatient-based laronidase enzyme replacement therapy for mucopolysaccharidosis I
por: Wilson, Amanda, et al.
Publicado: (2021)

Long-Term Outcomes of Early Enzyme Replacement Therapy for Mucopolysaccharidosis IV: Clinical Case Studies of Two Siblings
por: Barak, Sharon, et al.
Publicado: (2020)

Natural progression of cardiac features and long-term effects of enzyme replacement therapy in Taiwanese patients with mucopolysaccharidosis II
por: Lin, Hsiang-Yu, et al.
Publicado: (2021)

Mucopolysaccharidosis Type I
por: Kubaski, Francyne, et al.
Publicado: (2020)

Whole Exome Sequencing Identifies an Adult-Onset Case of Methylmalonic Aciduria and Homocystinuria Type C (cblC) with Non-Syndromic Bull’s Eye Maculopathy
por: Collison, Frederick T., et al.
Publicado: (2015)

Spontaneous resolution of subfoveal perfluorocarbon
por: Oellers, Patrick, et al.
Publicado: (2015)

Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study
por: Ficicioglu, Can, et al.
Publicado: (2020)

Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries
por: Magner, Martin, et al.
Publicado: (2022)

Dose-dependent effects of enzyme replacement therapy on skeletal disease progression in mucopolysaccharidosis VII dogs
por: Gawri, Rahul, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o0u0t1so8dvum2cvb8g7djdeif